All In Biotech

BLA 761151 · Ucb INC

Bimzelx

Bimekizumab-Bkzx · Injection

Novel

CDER novel approval, Oct 17, 2023: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 17, 2023

Approved uses

6

Original approval plus efficacy supplements

Registered trials

56

25 Phase 3, 9 recruiting

FAERS reports

26,321

8,343 serious, 184 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) 1.1 Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis BIMZELX is indicated for the treatment of adults with active psoriatic arthritis. 1.3 Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 1.4 Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis. 1.5 Hidradenitis Suppurativa BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa.

Mechanism: Bimekizumab-bkzx is a humanized immunoglobulin IgG1/ κ monoclonal antibody with two identical antigen binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex. IL-17A and IL-17F are naturally occurring cytokines that are involved in normal inflammatory and immune responses. Bimekizumab-bkzx inhibits the release of proinflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BIMZELX · BIMEKIZUMAB-BKZX 160ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bimekizumab" as an intervention, any sponsor and status, largest first.

All 56 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue4,798
  • psoriasis3,204
  • drug ineffective2,544
  • off label use2,157
  • hidradenitis2,041
  • condition aggravated1,885
  • psoriatic arthropathy1,876
  • injection site pain1,487
  • inappropriate schedule of product administration1,205
  • therapy interrupted1,187
  • pruritus1,119
  • pain1,096

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20191
20203
20216
202213
2023126
20242,720
202510,928
202612,523

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bimzelx (Bimekizumab-Bkzx)

2024 spending

$7.6M

Beneficiaries

134

509 claims

Per beneficiary

$56,469

$7,220.23 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$299,437
2024$7,566,799

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.